Sartorius Stedim Biotech launches NBE product characterization service

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, announced the launch of services for new biological entities, called NBE Product Characterization.

Sartorius Stedim BioOutsource’s testing services are fully customizable for clients to ensure their innovator drugs are tested based on the right regulatory requirements.
Sartorius Stedim BioOutsource’s testing services are fully customizable for clients to ensure their innovator drugs are tested based on the right regulatory requirements.

The services are offered by its subsidiary, Sartorius Stedim BioOutsource, an experienced, industry-leading contract testing organization based in Glasgow, UK, and in Cambridge, Massachusetts, USA.

Sartorius Stedim BioOutsource provides a comprehensive range of testing for innovator molecules available either as off-the-shelf assays or custom assay development for more complex proteins. Such tests include cell-based potency assays, bioassays and binding assays, as well as physicochemical and structural analyses, enabling customers to benefit from a fully integrated package.

These testing services are fully customizable for clients to ensure their innovator drugs are tested based on the right regulatory requirements by expert scientists.

Robust data packages proving the safety, purity and potency as required by the regulatory authorities will smooth the submissions process for approval by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

As a result of these fully customizable methods and data packages available for monoclonal antibody characterization that complement BioOutsource’s and Sartorius Stedim Cellca’s existing innovative offer for biologics, pharmaceutical companies can now work with one contract partner from cell line development to qualification and validation of analytical and biological product characterization assays.

We are really excited to bring to market this combined package of assay development and customizable off-the-shelf solutions for product characterization.

With our unrivaled experience in biosimilars testing, combined with our proven expertise in NBE assay development, we have developed a panel of assays suitable for mAb characterization.

This allows drug developers to fast-track complex bioassay development using our platform methods. With fully compliant cGMP facilities, we support our customers from early phase development to late phase and commercial release."

Jennifer Lawson, Product Manager, Sartorius Stedim BioOutsource

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sartorius. (2019, June 19). Sartorius Stedim Biotech launches NBE product characterization service. News-Medical. Retrieved on December 14, 2019 from https://www.news-medical.net/news/20190124/Sartorius-Stedim-Biotech-launches-services-for-characterization-of-new-biological-entities.aspx.

  • MLA

    Sartorius. "Sartorius Stedim Biotech launches NBE product characterization service". News-Medical. 14 December 2019. <https://www.news-medical.net/news/20190124/Sartorius-Stedim-Biotech-launches-services-for-characterization-of-new-biological-entities.aspx>.

  • Chicago

    Sartorius. "Sartorius Stedim Biotech launches NBE product characterization service". News-Medical. https://www.news-medical.net/news/20190124/Sartorius-Stedim-Biotech-launches-services-for-characterization-of-new-biological-entities.aspx. (accessed December 14, 2019).

  • Harvard

    Sartorius. 2019. Sartorius Stedim Biotech launches NBE product characterization service. News-Medical, viewed 14 December 2019, https://www.news-medical.net/news/20190124/Sartorius-Stedim-Biotech-launches-services-for-characterization-of-new-biological-entities.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Sartorius Stedim Biotech introduces new ambr 15 cell culture microbioreactor system